Currently, the world is witnessing a health crisis in the form of COVID-19 pandemic. For oncologists, especially for stem cell transplant specialists, the stress is high to perform to their best of capability for their cancer patients. In general, the hematopoietic stem cell transplantation (HSCT) is a high-risk procedure. The novelty of the COVID-19 disease, lack of literature, absence of antiviral agent, and vaccine has added more uncertainty while preparing for and recovering from HSCT.